Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 7/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | PPARG | P37231 | 7/20 | 0.43 |
| ▸ | PPARD | Q03181 | 7/20 | 0.43 |
| ▸ | PPARA | Q07869 | 7/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5351480 | 1.00 | ALDH1A1 (0.72) | ALDH1A1LMNATSHRNFKB1PMP22 | |
| SCHEMBL5355625 | 1.00 | ALDH1A1 (0.72) | ALDH1A1LMNATSHRNFKB1PMP22 | |
| SCHEMBL23191004 | 1.00 | ALDH1A1 (0.72) | ALDH1A1LMNATSHRNFKB1PMP22 | |
| SCHEMBL30008592 | 1.00 | ALDH1A1 (0.72) | ALDH1A1LMNATSHRNFKB1PMP22 | |
| SCHEMBL3628969 | 0.98 | ALDH1A1 (0.76) | ALDH1A1LMNATSHRNFKB1PMP22 | |
| SCHEMBL14010816 | 0.98 | ALDH1A1 (0.76) | ALDH1A1LMNATSHRNFKB1PMP22 | |
| SCHEMBL28550528 | 0.98 | ALDH1A1 (0.76) | ALDH1A1LMNATSHRNFKB1PMP22 | |
| SCHEMBL8262823 | 0.98 | ALDH1A1 (0.76) | ALDH1A1LMNATSHRNFKB1PMP22 | |
| SCHEMBL8269056 | 0.98 | ALDH1A1 (0.76) | ALDH1A1LMNATSHRNFKB1PMP22 | |
| SCHEMBL12592828 | 0.98 | ALDH1A1 (0.76) | ALDH1A1LMNATSHRNFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737477-A2 | HEPCIDIN MIMETICS FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS | Protagonist Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4706671-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250360187-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4025592-B1 | CONJUGATED HEPCIDIN MIMETICS FOR USE IN TREATING OF POLYCYTHEMIA VERA | PROTAGONIST THERAPEUTICS INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250304624-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-12234300-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4501952-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240293511-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS | PROTAGONIST THERAPEUTICS, INC. | 2024-09-05 | — | — | US | disclosed |
| US-20240209024-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240016895-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | PROTAGONIST THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11753443-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220372099-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2022-11-24 | — | — | US | disclosed |
| US-11472842-B2 | Analogues of hepcidin mimetics with improved in vivo half lives | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472842-B2 | Analogues of hepcidin mimetics with improved in vivo half lives | HAMP, VIP, HDGF | ALDH1A1 4175/4885LMNA 1559/4885TSHR 511/4885 |
| US-20240209024-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | ALDH1A1 3616/4885LMNA 1721/4885TSHR 652/4885 |
| US-12234300-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | ALDH1A1 3616/4885LMNA 1721/4885TSHR 652/4885 |
| US-20240293511-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS | HAMP, SLC40A1, FTH1 | ALDH1A1 3685/4885LMNA 1846/4885TSHR 758/4885 |
| US-11753443-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | ALDH1A1 3616/4885LMNA 1721/4885TSHR 652/4885 |
| US-20240016895-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | HAMP, HBG1, HBG2 | ALDH1A1 3526/4885LMNA 1752/4885TSHR 1607/4885 |
| US-20250360187-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | HAMP, HBG1, HBG2 | ALDH1A1 3526/4885LMNA 1752/4885TSHR 1607/4885 |
| US-20220372099-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, HDGF, FTH1 | ALDH1A1 2764/4885LMNA 1871/4885TSHR 840/4885 |
| US-20250304624-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | ALDH1A1 3616/4885LMNA 1721/4885TSHR 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.